

1 **Comorbidities associated with chronic kidney disease among young people living with HIV in**
2 **Uganda. A nested case control study**

3 Esther M Nasuuna^{1,2,3}, Laurie A Tomlinson⁴, Robert Kalyesubula^{1,5}, Barbara Castelnovo², Nicholus
4 Nanyeenya⁶, Chido Dziva Chikwari^{7,8}, Helen A Weiss⁸

5 *1 Non-communicable Diseases Program, Medical Research Council/Uganda Virus Research Institute*
6 *and London School of Hygiene and Tropical Medicine Uganda Research Unit, Plot 51-59 Nakiwogo*
7 *Road, Entebbe Uganda*

8 *2 Infectious Diseases Institute, Makerere University, College of Health Sciences, P.O.Box 22418*
9 *Kampala, Uganda*

10 *3 Department of Infectious Disease Epidemiology and International Health, London School of*
11 *Hygiene and Tropical Medicine, Keppel St, London WC1E 7HT, United Kingdom.*

12 *4 Department of non-Communicable Disease Epidemiology, London School of Hygiene and Tropical*
13 *Medicine, Keppel St, London WC1E 7HT, United Kingdom*

14 *5 Department of Physiology and Department of Medicine, Makerere University College of Health*
15 *Sciences, P.O. Box 7072, Kampala, Uganda*

16 *6 School of Public Health, Makerere University College of Health Sciences, P.O. Box 7072, Kampala,*
17 *Uganda*

18 *7 Biomedical Research and Training Institute, 10 Seagrave Avondale, Harare, Zimbabwe*

19 *8 MRC International Statistics and Epidemiology Group, London School of Hygiene & Tropical*
20 *Medicine, Keppel St, London WC1E 7HT, United Kingdom*

21

22 *Corresponding author*

23 *Esther M Nasuuna*

24 *Esther.nasuuna@lshtm.ac.uk*

25

26 Laurie A Tomlinson: laurie.tomlinson@lshtm.ac.uk

27 Robert Kalyesubula: rkalyesubula@gmail.com

28 Barbara Castelnovo: bcastelnovo@gmail.com

29 Nicholus Nanyeenya: nanyeenya@gmail.com

30 Chido Dziva Chikwari: chidodziva.chikwari@lshtm.ac.uk

31 Helen A Weiss: helen.weiss@lshtm.ac.uk

32

33

34 **Abstract**

35 **Introduction**

36 Chronic kidney disease (CKD) is often complicated by disorders in multiple body systems, associated
37 with higher mortality and morbidity. Young people living with HIV (YPLHIV) have an increased risk
38 of multisystem chronic comorbidities. However, there are few data describing comorbidities
39 associated with CKD among YPLHIV.

40 **Methods**

41 We conducted a case-control study in seven ART clinics in Kampala, Uganda. Cases were YPLHIV
42 (aged 10-24 years) diagnosed with CKD and controls were those without CKD. We collected data on
43 demographic and clinical factors: blood pressure, fasting glucose levels, anaemia, electrolytes,
44 parathyroid hormone, and cognitive impairment. We summarized the demographic and clinical factors
45 and used logistic regression to estimate odds ratios (OR) and 95% confidence intervals for
46 associations between CKD comorbidities, adjusted for age, sex and viral suppression.

47 **Results**

48 A total of 292 participants (96 cases and 196 controls) were recruited. Cases were mostly male (59.4%
49 vs 36.5%), and younger (88.5% vs 46.4% aged <17 years) compared to controls. CKD was associated
50 with having a detectable HIV viral load (OR=3.73; 95% CI 1.53-9.12) and proteinuria (aOR=4.19;
51 95% CI 2.28-7.72). CKD was also associated with low haematocrit, hypochloraemia,
52 hyperphosphatemia, and high mean corpuscular volume. There was no evidence of an association of
53 CKD with hypertension, anaemia, or stunting.

54 **Conclusion**

55 The pattern of comorbidities among YPLHIV with CKD is uncertain and difficulties may relate to
56 difficulty determining true kidney function and normal ranges in this population. Further studies are
57 needed to discern the pattern of CKD complications to improve management efforts and clinical
58 outcomes.

59 **Key words.** Chronic kidney disease, complications, young people living with HIV, Sub Saharan
60 Africa

61

62 **Introduction**

63 Chronic kidney disease (CKD) is often complicated by disorders in multiple body systems as the
64 kidneys play a pivotal role in homeostasis maintenance in the body [1]. With extensive damage and
65 progressive decline in function, the kidney is unable to perform its many functions and other body
66 systems are affected [2]. The most commonly affected systems are the haematological, cardiovascular,
67 endocrine, and musculoskeletal [3, 4]. CKD comorbidities and complications increase with reducing
68 kidney function and are associated with higher mortality, morbidity, and reduced quality of life [5].

69 In people with CKD, cardiovascular complications such as congestive cardiac failure, arrhythmias,
70 and coronary artery disease are common, and are leading cause of mortality [6, 7]. Hypertension also
71 commonly complicates CKD and leads to faster deterioration in glomerular filtration rate [8].

72 Anaemia is the commonest haematological complication of CKD resulting partially from the reduced
73 production of erythropoietin in the damaged kidneys [4]. In the musculoskeletal system, disordered
74 bone mineral metabolism of calcium, phosphorus and parathyroid hormone leads to osteodystrophy
75 and osteoporosis that predispose to fractures and stunting in children [9-11]. The most common
76 neurological complications are cognitive impairment, stroke, encephalopathy, autonomic and
77 peripheral neuropathies [3, 12]. If these complications are undiagnosed and untreated, they will
78 eventually lead to death [2].

79 Young people living with HIV (YPLHIV) have an increased risk of multisystem chronic
80 comorbidities as a result of the HIV infection itself [13]. When YPLHIV develop CKD, the risk of
81 comorbidities is increased due to the additional burden of gradual deterioration in kidney function [5,
82 14]. There is a poorly understood complex interplay between HIV and CKD that makes it difficult to
83 determine if HIV or CKD or their combination is driving the development of the complications [15].
84 Current literature that is derived mostly from high income countries, describes the presentation and

85 comorbidities of CKD in adults that are mostly caused by living with hypertension and diabetes, or in
86 children with mostly congenital causes [16]. These comorbidities may differ from those in young
87 adults living with HIV and CKD in LMICs, and we need to understand such differences, especially if
88 they have clinical implications.

89 Kidney disease improving global outcomes (KDIGO) recommends the consistent documentation of
90 all laboratory abnormalities in different populations with CKD to inform management practices and
91 improve associated quality of life, morbidity and mortality [5]. Therefore, we sought to describe the
92 comorbidities and complications and associations with kidney function in YPLHIV in Uganda.

93 **Materials and Methods**

94 **Study design, setting and population.**

95 This case-control study with 96 cases and 196 controls was conducted in seven urban ART clinics in
96 Kampala, Uganda between November 2023 and January 2024.

97 **Sampling:** The cases were the YPLHIV (aged 10 to 24 years) diagnosed with CKD. This was
98 defined as an eGFR below $90\text{ml}/\text{min}/1.73\text{m}^2$ on two separate occasions three or more months apart
99 using cystatin C based Schwartz equation [17] without restriction for age. We elected to use this
100 approach as sudden switch to adult formulae at age 18 have been shown to overestimate GFR and it
101 has been recommended to use paediatric formulae for adolescents and young adults up to age 30 when
102 concurrence between eGFR from adult and paediatric formulae happens [18, 19]. We used a cut off of
103 $90\text{ml}/\text{min}/1.73\text{m}^2$ and not the standard $<60\text{ml}/\text{min}/1.73\text{m}^2$ as we were studying a young population
104 where GFR well above $60\text{ml}/\text{min}/1.73\text{m}^2$ would have been anticipated in health, and stage 2 CKD is
105 diagnosed between 89 and $60\text{ml}/\text{min}/1.73\text{m}^2$ if there is evidence of persisting kidney damage [20-22].
106 Separately, we also described parameters among individuals with $\text{eGFR}<60\text{ml}/\text{min}/1.73\text{m}^2$. Serum
107 cystatin C was measured in a batch by particle-enhanced immunoturbidimetric assay on Roche Cobas
108 C311 platform with Tina-quant Cystatin C Gen.2 [23].

109 The controls were the YPLHIV attending the same clinics with an eGFR equal to or above
110 90ml/min/1.73m² determined with the same methods as the cases. We recruited two controls for each
111 case.

112 **Study procedures:** Participants were invited to the facility where they were interviewed about current
113 medication and hospitalisation. Data were collected on the demographic variables (age, sex, religion,
114 school status, tribe, address). School status was either in school or out of school, address was collected
115 as either living in Kampala or out of Kampala. Clinical variables collected were: stunting according to
116 the WHO reference standard, body mass index calculated as weight over height squared, mid upper
117 arm circumference (MUAC) was measured using the UNICEF tapes according to the age of the
118 participant, HIV viral suppression was defined as an HIV viral load below 1000 cells/ml, proteinuria
119 was defined as either trace of 1+ and above on dipstick, albumin creatinine ratio (ACR) was measured
120 in the laboratory and whether or not the participant was on a tenofovir disoproxil fumarate (TDF)
121 based regimen.

122 The comorbidities assessed included hypertension, anaemia, impaired blood glucose, bone mineral
123 disease, electrolyte imbalance, stunting and cognitive impairment. Blood pressure (BP) was measured
124 digitally, using a paediatric cuff for the younger children. Participants were asked to sit down and
125 relax, and their BP was taken on the left arm with an OMRON Upper ARM Blood Pressure Monitor
126 HEM 7121J, (OMRON Healthcare Company Limited, Kyoto, Japan). The BP was taken twice, five
127 minutes apart and the mean of the two readings taken as the final BP. They then underwent a
128 cognitive function assessment using the Youth International HIV Dementia Scale (y-IHDS) [24].

129 Fasting blood glucose was measured using On Call Plus Blood Glucose Monitoring System (ACON
130 Laboratories, Inc, San Diego, United States of America) and a venous blood sample was taken. The
131 blood sample was analysed to determine values of serum electrolytes (potassium, chloride,
132 bicarbonate, phosphate, calcium), kidney function (creatinine, blood urea nitrogen) measured on the
133 Cobas 501/502 (Hitachi High technologies Corporation Tokyo, Japan). Haematological tests
134 (complete blood count and serum ferritin) and parathyroid hormone were measured on the Cobas

135 e601 (Hitachi High technologies Corporation Tokyo, Japan). All the samples were analysed in the
 136 College of American Pathologists (CAP) accredited MRC/UVRI laboratory in Uganda.

137 **Data analysis**

138 Data were collected in REDCap (2019, Vanderbilt University, USA) and exported to STATA
 139 statistical software version 18 (STATA Corp USA) for analysis. To take account of the changing
 140 reference values across the age group of this study, comorbidities were defined as in Table 1.

141 **Table 1 Reference Ranges for the assessed comorbidities among the participants**

Variable	Reference range
Blood pressure (mmHg)	Elevated blood pressure was between 90 th and 95 th percentile for age, sex, and height. Hypertension was above 95 th percentile for children aged less than 13 years. Those above 13 years of age were considered hypertensive if the blood pressure was above 130/80 [8]
Fasting blood glucose (mg/dl)	Normal 70-100, Prediabetes 100-125 Diabetic >126 [25].
Haemoglobin (g/dl)	11.5 <11 years , 11.9 11 and 15 years, females >15 years 12.9 for males >15 years [26].
Ferritin (ng/mL)	12-300 for males >15 years 10-150 for females > 15 years 7-142 males and females 10-14 years (20).
Red blood cells	4.7-6.1 for males 4.2-5.4 for females
Haematocrit	0.35-0.48 for all ages [27]
Mean Corpuscular Volume (MCV) (fL)	77.8-91.1 males 6-11 years 79.9-93.0 males 12-14 years 82.5-98.0 males 15-17 years 78.2-97.9 males >18 years 77.8-91.1 females: 6-11 years 79.9-93.0 females 12-14 years 82.5-98.0 females 15-17 years 78.2-97.9 females >18 years [28].
Mean Corpuscular Haemoglobin (MCH)	25-33 pg/cell for all ages and sexes [29].
White blood cells (µL)	4-10.5 X 10 ³ / for all ages and sexes
Platelets	150-400 for all ages [27]
Parathyroid hormone (pg/ml)	15-59 for 10 years, 15-68 for 11 to 17 years 15-65 for 8 to 24 years [30].
Serum calcium (mg/dl)	9.4-10.3 for 10 to 12 years 9.1-10.2 for males aged 12 to 24 years. 8.8-10 for females aged 12 and above [31].

Serum Phosphate (mg/dl)	3.6-5.8 for 10 -12 years, 2.3-4.5 for 12 -20 years [32]. 2.5 to 4.5 for 21 to 24 years [33].
Blood urea nitrogen (mg/dl)	6-20 for 10-to-17-years 8-24 for males 18 to 24 years, 7-2 for females 18-24 years [34].
Serum Potassium (mmol/l)	3.6-5.2 for all ages [34].
Serum chloride (mmol/l)	102-112 for 10 to 17 years 98 to 107 for 18 to 24 years [34].
Serum bicarbonate (mmol/l)	21-29 in males 22-29 in females [34].
Cognitive impairment	<10 on the (y-IHDS) [24].

142

143 **Statistical methods**

144 Demographic and clinical characteristics were summarised by case/control status as number and
145 percentage (categorical variables), and means and standard deviations, or medians and interquartile
146 ranges (continuous variables) for the parametric data. A subgroup analysis of the cases that had eGFR
147 <60ml/min/1.73m² was also conducted. Associations of case/control status with comorbidities were
148 assessed using logistic regression to estimate odds ratios and 95% CI. In modelling adjusted odds
149 ratios for the association between case/control status and haematological or biochemical covariates we
150 adjusted for age as a continuous variable, sex and viral suppression. P-values were estimated using
151 likelihood-ratio tests. Post-hoc, to explore the extent to which differences in biochemical and
152 haematological parameters were affected by adherence to anti-retroviral medication, we also
153 conducted an analysis restricting to cases and controls who were virally suppressed. We also assessed
154 the relationship between eGFR and selected haematological and biochemical factors using scatter
155 plots and correlation coefficients to determine how they changed with changes in eGFR.

156 **Results**

157 We recruited 96 cases and 196 controls. Cases were more likely to be male (59.4% vs 36.2%) and to
158 be younger (88.5% vs 46.4%) with a lower mean age compared to controls (15.3 years vs 17.8 years).
159 After adjusting for age and sex, cases were more likely to be virally non suppressed, have proteinuria,
160 and to have ACR above 30mg/g (Table 2).

161 **Table 2: Distribution and associations of CKD with demographic and clinical characteristics** 162 **among YPLHIV**

Variable	Total N=292	Case N=96	Control N=196	OR (95% CI)*	P value
Sex					
Male	128 (43.8%)	57 (59.4%)	71 (36.2%)	1	
Female	164 (56.2%)	39 (40.6%)	125 (63.8%)	0.39 (0.23-0.64)	<0.001
Age (years)#					
10-17	16.9 (3.6)	15.3 (2.8)	17.8 (3.6)	0.80 (0.74-0.87)	<0.001
18-24	176 (60.3%)	85 (88.5%)	91 (46.4%)	1	
	116 (39.7%)	11 (11.5%)	105 (53.6%)	0.11 (0.06-0.22)	<0.001
Address					
Kampala	175 (59.9%)	57 (59.4%)	118 (60.2%)	1	
Wakiso	101 (34.6%)	34 (35.4%)	67 (34.2%)	1.05 (0.62-1.77)	0.97
Other	16 (5.5%)	5 (5.2%)	11 (5.6%)	0.94 (0.31-2.83)	
Religion					
Christian	207 (70.9%)	65 (67.7%)	142 (72.4%)	1	
Moslem	83 (28.4%)	31 (32.3%)	52 (26.5%)	1.30 (0.76-2.22)	0.33
Other	2 (0.7%)	0 (0.0%)	2 (1.0%)	-	
Social Economic Status					
Lowest	100 (34.3%)	35 (36.5%)	65 (33.2%)	1	
Middle	97 (33.2%)	34 (35.4%)	63 (32.1%)	1.00 (0.55-1.79)	0.53
Highest	95 (32.5%)	27 (28.1%)	68 (34.7%)	0.73 (0.40-1.35)	
Is child in school					
No	85 (29.1%)	20 (20.8%)	65 (33.2%)	1	
Yes	207 (70.9%)	76 (79.2%)	131 (66.8%)	1.89 (1.06-3.35)	0.03
Marital Status					
Married	14 (4.8%)	2 (2.1%)	12 (6.1%)	1	
Never married	278 (95.2%)	94 (97.9%)	184 (93.9%)	3.07 (0.67-13.97)	0.10
Tribe					
Ganda	188 (64.4%)	67 (69.8%)	121 (61.7%)	1	0.13
Other tribes	88 (30.1%)	22 (22.9%)	66 (33.7%)	0.60 (0.34-1.06)	
Non-Ugandan	16 (5.5%)	7 (7.3%)	9 (4.6%)	1.40 (0.50-3.94)	
Body mass Index					
Normal	166 (60.6%)	41 (43.2%)	136 (69.4%)	1	<0.39
Underweight (BMI<19)	86 (31.4%)	49 (51.6%)	43 (21.9%)	1.44 (0.71-2.92)	
Overweight (BMI>25)	22 (8.0%)	5 (5.3%)	17 (8.7%)	1.77 (0.57-5.50)	
Mid upper arm circumference					
Normal	264 (90.7%)	84 (88.4%)	180 (91.8%)	1	
Malnourished	27 (9.3%)	11 (11.6%)	16 (8.2%)	1.47 (0.65-3.31)	0.35
Weight (Kg)#					
	49.9 (12.1%)	45.35 (11.1%)	52.18 (11.9%)	0.95 (0.93-0.97)	<0.001
Muscle mass					
Normal muscle mass	235 (84.5%)	74 (84.1%)	161 (84.7%)	1	
Abnormal muscle mass	43 (15.5%)	14 (15.9%)	29 (15.3%)	1.05 (0.52-2.10)	0.89
TDF based regimen					
No TDF or ATV	69 (23.6%)	28 (29.2%)	41 (20.9%)	1	
On TDF or ATV	223 (76.4%)	68 (70.8%)	155 (79.1%)	0.64 (0.36-1.12)	0.12
Virally suppressed (VL <1,000 copies per ml)					

Yes	263 (90.4%)	80 (83.3%)	183 (93.8%)	1	
No	28 (9.6%)	16 (16.7%)	12 (6.2%)	3.73 (1.53-9.12)	0.006
Proteinuria					
Negative	203 (69.5%)	52 (54.2%)	151 (77.0%)	1	
Positive	89 (30.5%)	44 (45.8%)	45 (23.0%)	4.19 (2.28-7.72)	<0.001
Albumin creatinine ratio					
Below 30mg/g	261 (89.4%)	75 (78.1%)	186 (94.9%)	1	
Above 30mg/g	31 (10.6%)	21 (21.9%)	10 (5.1%)	6.43 (2.67-15.48)	<0.001


163 *adjusted for age and sex # mean and standard deviation. Proteinuria was measured on dipstick

164

165 **Associations between CKD and comorbidities among YPLHIV**

166 Cases had lower odds of having a high MCV (aOR=0.24, 95% CI 0.09-0.64), and higher odds of
 167 hyperphosphatemia (aOR=3.66, 95% CI 1.21 -5.84), and higher odds of hyperchloremia (aOR=2.55,
 168 95%CI 1.36 -4.77), after adjustment for age, sex, and viral suppression. There was no evidence of an
 169 association between CKD and blood pressure, impaired blood glucose, other biochemical and
 170 haematological parameters and cognitive function. These results did not change when analysis was
 171 restricted to those who were virally suppressed (Table 3). Analysis of eGFR and selected variables
 172 showed no correlation between eGFR and those variables. (Figure 1). Of note, two participants had
 173 potassium levels below 3.5mmol/l and six had elevated levels above 6 mmol/l and 125 (42.8%) were
 174 acidotic. Results for the cases that had eGFR <60ml/min/1.73m² are reported in supplementary tables
 175 1 and 2.

176 **Figure 1 Relationship between eGFR and selected biochemical markers**



177

178 **Cases with eGFR<60mls/min/1.73m²**

179 Of the seven participants with eGFR <60ml/min/1.73m², five were male, below 18 years of age and
 180 on a TDF based regimen, three had proteinuria and five had an ACR above 30mg/g. The mean
 181 systolic blood pressure was lower than that of the participants with eGFR below 90ml/min/1.73m² and
 182 only one was hypertensive, two had prediabetic range blood glucose levels, one had anaemia, two had
 183 leukopenia, one had thrombocytosis and four had increased levels of parathyroid hormone and 5 had
 184 impaired cognition (Table 3).

185 **Table 3: Distribution and associations of CKD with comorbidities among PLWH**

Variable	Total n=292	Case (n=96)	Control (n=196)	Adjusted OR for age, sex and viral suppression	P value	Restricted to virally suppressed N=263
Blood pressure (mmhg)						
Systolic blood pressure ^a	111.7 (12.1)	110.9 (12.0)	112.1 (12.1)			
Diastolic blood pressure ^a	71.4 (8.8)	69.8 (8.9)	72.1 (8.7)			
Normal	204 (69.9%)	67 (69.8%)	137 (69.9%)	1		1
Elevated	38 (13.0%)	14 (14.6%)	24 (12.2%)	1.05 (0.48- 2.35)	0.93	0.99 (0.43-2.24)
Hypertensive	50 (17.1%)	15 (15.6%)	35 (17.9%)	1.15 (0.54- 2.47)		1.14 (0.49-2.64)
Blood Sugar (mg/dl)						
Blood glucose ^a	94.1 (15.2)	93.7 (16.2)	94.2 (14.6)			
Normal	205 (70.2)	65 (67.7%)	140 (71.4%)	1		1

Prediabetic	78 (26.7)	28 (29.2%)	50 (25.5%)	1.03 (0.56-1.92)	0.99	0.83 (0.42-1.64)
Diabetic	9 (3.1)	3 (3.1%)	6 (3.1%)	1.08 (0.24-4.96)		1.47 (0.30-7.19)
Anaemia status (g/dl)						
Haemoglobin ^a	13.3 (1.7)	13.4 (1.3)	13.3 (1.9)			
No anaemia	229 (78.4%)	76 (79.2%)	153 (78.1%)	1		1
Anaemic	63 (21.6%)	20 (20.8%)	43 (21.9%)	1.12 (0.58-2.19)	0.73	1.09 (0.54-2.19)
Serum Ferritin (ng/ml)						
Ferritin ^b	36.4 (18.8-69.3)	45.1 (22.5-72.4)	34.0 (15.6-64.1)			
Normal	254 (86.9)	86 (86.9%)	168 (85.7%)	1		1
Low ferritin	23 (7.9)	4 (4.2%)	19 (9.7%)	0.67 (0.21-2.18)	0.88	0.81 (0.24-2.69)
High ferritin	15 (5.2)	6 (6.2%)	9 (4.6%)	1.42 (0.41-4.94)		1.70 (0.44-6.48)
Red blood cells (10⁶/μL)						
Absolute count ^a	4.8 (0.6)	4.9 (0.6)	4.7 (0.6)			
Normal count	209 (71.6)	67 (69.8)	142 (72.5)	1		1
Low count	68 (23.3)	24 (25.0)	44 (22.5)	0.62 (0.30-1.25)	0.39	0.56 (0.26-1.21)
High count	15 (5.1)	5 (5.2)	10 (5.0)	0.86 (0.26-2.89)		0.93 (0.25-3.49)
Haematocrit (%)						
Haematocrit ^a	41.6 (4.92)	41.9 (3.9)	41.4 (5.4)			
Normal	242 (82.9)	89 (92.7)	153 (78.1)	1		1
Low haematocrit	19 (6.5)	1 (1.0)	18 (9.2)	0.12 (0.02-1.17)	0.01	-
High haematocrit	131 (10.6)	6 (6.3)	25 (12.8)	0.38 (0.13-1.06)		0.35 (0.11-1.03)
Mean Corpuscular volume (MCV) (pg)						
MCV ^a	87.3 (8.4)	86.5 (7.4)	87.7 (8.8)			
Normal	200 (68.5)	68 (70.8%)	132 (67.3%)	1		1
Low MCV	53 (18.2)	20 (20.8%)	33 (16.8%)	1.17 (0.58-2.38)	0.02	1.19 (0.57-2.48)
High MCV	39 (13.6)	8 (8.3%)	31 (15.8%)	0.24 (0.09-0.64)		0.19 (0.07-0.58)
White blood cell count (μL)						
Absolute ^b	4.9 (4.0-5.9)	5.0 (4.1-6.0)	4.9 (4.0-5.9)			
Normal	223 (76.4)	75 (78.1)	148 (75.5)	1		1
Leukopenia	68 (23.3)	21 (21.9)	47 (24.0)	0.87 (0.45-1.68)	0.67	1.08 (0.53-2.18)
Leucocytosis	1 (0.3)	0 (0.0)	1 (0.5)	-		-
Platelets (10³/μL)						
Count ^a	342.5 (90.9)	332.6 (75.2)	347.3 (97.5)			
Normal	258 (88.4)	88 (91.7)	170 (86.7)	1		1
Thrombocytopenia	2 (0.7)	0 (0.0)	2 (1.0)	-		-
Thrombocytosis	32 (10.9)	8 (8.3)	24 (12.2)	0.58 (0.23-1.47)	0.25	0.46 (0.17-1.23)
Parathyroid hormone (pg/ml)						
PTH ^b	57.7 (42.6-79.3)	62.7 (44.9-80.3)	55.6 (42-79.1)			
Normal parathyroid	183 (62.7)	57 (59.4%)	126 (64.3%)	1		1
Hyperparathyroidism	109 (37.3)	39 (40.6%)	70 (35.7%)	0.87 (0.50-1.57)	0.68	0.74 (0.40-1.36)
Serum Calcium (mg/dl)						
Calcium ^a	2.30 (0.1)	2.29 (0.17)	2.28 (0.11)			
Normal	194 (66.4)	61 (63.5%)	133 (67.9%)	1		1
Hypocalcaemia	94 (32.2)	34 (35.4%)	60 (30.6%)	0.55 (0.29-1.04)	0.11	0.42 (0.21-0.86)
Hypercalcemia	4 (1.4)	1 (1.0%)	3 (1.5%)	1.37 (0.12-15.17)		2.68 (0.19-37.3)
Serum Phosphate (mg/dl)						
Phosphate ^b	1.2 (1.0-1.4)	1.4 (1.1-1.5)	1.1 (0.95-1.3)			

Normal	242 (82.9)	70 (72.9%)	172 (87.7%)	1	1
Hypophosphatemia	11 (3.8)	2 (2.1%)	9 (4.6%)	0.89 (0.17-4.58)	0.02 0.92 (0.17-4.75)
Hyperphosphatemia	39 (13.4)	24 (22.0%)	15 (7.7%)	2.56 (1.21-5.42)	2.59 (1.18-5.67)
Blood Urea Nitrogen (mg/dl)					
BUN ^a	2.7 (0.9)	2.8 (0.93)	2.7 (0.83)		
Normal	167 (57.2%)	58 (72.2%)	109 (55.6%)	1	1
Hypouremia	125 (42.8%)	22 (27.8%)	87 (44.4%)	0.79 (0.45-1.39)	0.43 0.80 (0.44-1.44)
Serum Potassium (mmol/l)					
Potassium ^a	4.7 (0.5)	4.8 (0.53)	4.6 (0.52)		
Normal	257 (88.0%)	82 (85.4%)	175 (89.3%)	1	1
Hypokalaemia	2 (0.7%)	0 (0.0%)	2 (1.0%)	-	-
Hyperkalaemia	33 (11.3%)	14 (14.6%)	19 (9.7%)	1.52 (0.67-3.44)	0.37 1.61 (0.69-3.71)
Serum Chloride (mmol/l)					
Chloride ^a	103.2 (8.6)	103.1 (9.19)	103.3 (8.36)		
Normal	197 (67.5%)	58 (60.4%)	139 (70.9%)	1	1
Hypochloraemia	19 (6.5%)	6 (6.3%)	13 (6.6%)	1.26 (0.40-3.97)	0.99 (0.29-3.40)
Hyperchloremia	76 (26.0%)	32 (33.3%)	44 (22.5%)	2.43 (1.28-4.59)	0.02 2.37 (1.2-4.68)
Serum Bicarbonate (mmol/l)					
Bicarbonate ^a	20.6 (2.6)	20.2 (2.4)	20.7 (2.6)		
Normal	103 (35.3%)	32 (33.3%)	71 (36.2%)	1	1
Low bicarbonate	188 (64.4%)	64 (66.7%)	124 (63.3%)	1.24 (0.67-2.26)	0.49 1.19 (0.63-2.24)
High bicarbonate	1 (0.3%)	0 (0.0%)	1 (0.5%)	-	-
Stunting					
Not stunted	171 (82.2%)	66 (75.9%)	105 (86.8%)	1	1
Stunted	37 (17.8%)	21 (24.1%)	16 (13.2%)	1.57 (0.71-3.47)	0.26 1.28 (0.55-2.99)
Cognition					
Normal	169 (57.9%)	48 (50.0%)	121 (61.7%)	1	1
Impaired	123 (42.1%)	48 (50.0%)	75 (38.3%)	1.42 (0.81-2.52)	0.22 1.40 (0.77-2.55)

186

187 Discussion

188 We set out to assess comorbidities associated with CKD among YPLHIV in Uganda. YPLHIV with
 189 CKD were more likely than controls to have hyperphosphatemia and hyperchloremia and were less
 190 likely to have high MCV and high haematocrit. Although the prevalence of common comorbidities
 191 such as hypertension, anaemia, impaired glucose metabolism, cognitive impairment and stunting was
 192 high, they were not associated with having CKD among the YPLHIV in this study.

193 We included a sufficiently large number of cases and controls and assessed multi body systems for
 194 comorbidities. There is little literature on the comorbidities faced by young people with the double
 195 burden of CKD and HIV in SSA. This is surprising given that 90% of young people living with HIV
 196 reside in SSA and they are at high risk of developing complications of HIV such as CKD [35, 36].

197 Findings from the current study are thus discussed here in comparison with those in either young
198 people living with CKD and not HIV, or with YPLHIV or adults with CKD in the general population.

199 We might not have observed substantial differences between YPLHIV with CKD and those without
200 for a variety of reasons. 1) HIV itself causes similar complications to CKD in the cardiovascular,
201 musculoskeletal, and haematological systems, including stunting [13]. The cases were more likely to
202 have HIV viral non-suppression, an important difference since uncontrolled HIV can lead to more
203 complications. 2) The cases (except for the seven with $eGFR < 60 \text{ ml/ml/1.73m}^2$) were still in the early
204 stages of CKD with an $eGFR$ between 60 and 90 ml/min/1.73m^2 , most complications develop with
205 later stages of CKD [37]. 3) CKD status of the controls was determined only at baseline, any of them
206 could have developed an $eGFR$ less than 90 ml/min/1.73m^2 during the follow up time, making them a
207 case and obscuring the differences. 4) Discerning participants with derangements in the biochemical
208 and haematological markers was also challenging. Reference values for most of these markers were
209 derived from American populations and those of African populations are mostly unknown [38]. Using
210 these values could have led to misclassification of the YPLHIV and obscured associations [39].

211 This study shows that the cases have started developing complications and could get worsening
212 kidney function and eventual kidney failure. The cases had hyperphosphatemia, but not low calcium.
213 This was also true for the CKiD study in the United States of America that enrolled children with
214 CKD, mostly of congenital origin. As GFR decreased, hyperphosphatemia and increased levels of
215 PTH and eventually low levels of calcium emerged [40]. The cases in this study may be on their way
216 to developing bone mineral disease which is associated with cardiovascular events, cognitive
217 impairment and stunting [41]. The cases in our study had higher levels of serum chloride than
218 controls. Serum chloride has been suggested as predictor of CKD progression and could show that the
219 YPLHIV are in danger of CKD progression [42]. Of concern, we have identified people with both
220 dangerously high and low potassium levels. We cannot exclude that these are due to haemolysis or
221 analytical errors,) but this highlights the importance of better monitoring and clinical management of
222 biochemical abnormalities in this vulnerable patient group.

223 YPLHIV with CKD have been shown to have atypical presentation patterns which are different from
224 adults living with HIV where we draw most of the comparisons [13]. For example, common
225 complications such as hypertension and anaemia were not associated with CKD in this study. A study
226 in Nigeria on 24 children 6 to 17 years of age with CKD and age and sex matched controls found that
227 prevalence of hypertension increased as the CKD stage increased [43]. The participants in this study
228 were not living with HIV and had more advanced stages of CKD compared to our participants.
229 Haemoglobin was not associated with eGFR in this study. Anaemia is more prevalent in advanced
230 stages of CKD with GFR less than 60 ml/min and since the YPLHIV were still in lower stages, this
231 could explain the lack of association [44, 45].

232 There is still a lot that is unknown about the comorbidities associated with CKD among YPLHIV. Our
233 results call for more studies that characterise the spectrum and presentation of chronic comorbidities
234 among YPLHIV with CKD for a more comprehensive understanding [5]. Comparison of YPLHIV
235 with CKD with HIV negative controls might explain the contribution of HIV.

236 **Conclusion**

237 The pattern of comorbidities among YPLHIV with CKD is uncertain and difficulties may relate to
238 difficulty determining true kidney function and normal ranges in this population. Further studies are
239 needed to discern the pattern of CKD complications to improve management efforts and clinical
240 outcomes.

241

242 **Ethical considerations**

243 This study was approved by the Uganda Virus Research Institute (UVRI) Research Ethics Committee
244 with reference number GC/127/946, the Uganda National Council of Science and Technology
245 (reference number HS2578ES) and the London School of Hygiene and Tropical Medicine (reference
246 28797). Informed consent/assent was provided by all participants. Age-appropriate information about
247 the study was provided prior to consent by the study nurses. All the participants aged more than 18
248 years provided a written informed consent. Those aged below 18 years (child) provided written assent

249 and their caregivers provided a written informed consent. The studies were conducted in accordance
250 with the declaration of Helsinki.

251 **Data availability**

252 The data that support the findings of this study are available from the corresponding author upon
253 reasonable request.

254 **Conflicts of interest**

255 The authors declare no conflict of interest.

256 **Funding statement**

257 Support for the PhD studies was provided by Fogarty International Centre, National Institutes of
258 Health (grant #2D43TW009771-06) HIV and co-infections in Uganda.

259 Esther Nasuuna, Doctoral Research Fellow, NIHR131273 is funded by the NIHR for this research
260 project. The views expressed in this publication are those of the author(s) and not necessarily those of
261 the NIHR, NHS or the UK Department of Health and Social Care.

262 **Acknowledgments**

263 We wish to acknowledge the participants, their caregivers and the facility staff where this study took
264 place. We also acknowledge the study team, Miss Evelyn Natuha, Miss Stella Mirembe and Mr.
265 Malcolm Lwanga. We acknowledge the KCCA leadership and the PEPFAR program that supports
266 HIV care for the YPLHIV.

267 **Supplementary material**

268 There are two tables in the supplementary material section that show the sub analysis of cases that had
269 an eGFR <60ml/min/1.73m².

270 Supplementary table 1: Demographic and clinical characteristics of the cases with eGFR less than
271 60ml/min/1.73m²

272 Supplementary table 2: Distribution of comorbidities in the cases with eGFR less than
273 60ml/min/1.73m²

274

275 **References**

- 276 1. Snively CS, Gutierrez C. Chronic kidney disease: prevention and treatment of common
277 complications. *American family physician*. 2004;70(10):1921-8.
- 278 2. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. *The*
279 *lancet*. 2021;398(10302):786-802.
- 280 3. Krishnan AV, Kiernan MC. Neurological complications of chronic kidney disease. *Nature*
281 *Reviews Neurology*. 2009;5(10):542-51.
- 282 4. Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. *Prim Care*.
283 2008;35(2):329-vii.
- 284 5. Bello AK, Alrukhaimi M, Ashuntantang GE, Basnet S, Rotter RC, Douthat WG, et al.
285 Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action.
286 *Kidney international supplements*. 2017;7(2):122-9.
- 287 6. Di Lullo L, House A, Gorini A, Santoboni A, Russo D, Ronco C. Chronic kidney disease and
288 cardiovascular complications. *Heart Failure Reviews*. 2015;20(3):259-72.
- 289 7. Sarnak MJ. Cardiovascular complications in chronic kidney disease. *American Journal of*
290 *Kidney Diseases*. 2003;41:11-7.
- 291 8. Flynn JT, Falkner BE. New Clinical Practice Guideline for the Management of High Blood
292 Pressure in Children and Adolescents. *Hypertension (Dallas, Tex : 1979)*. 2017;70(4):683-6.
- 293 9. Hou YC, Lu CL, Lu KC. Mineral bone disorders in chronic kidney disease. *Nephrology*.
294 2018;23:88-94.
- 295 10. Kaspar C, Bholah R, Bunchman T. A review of pediatric chronic kidney disease. *Blood*
296 *purification*. 2016;41(1-3):211-7.
- 297 11. Silverstein DM. Growth and nutrition in pediatric chronic kidney disease. *Frontiers in*
298 *pediatrics*. 2018;6:205.
- 299 12. Arnold R, Issar T, Krishnan AV, Pussell BA. Neurological complications in chronic kidney
300 disease. *JRSM Cardiovascular Disease*. 2016;5:2048004016677687.
- 301 13. Frigati LJ, Ameyan W, Cotton MF, Gregson CL, Hoare J, Jao J, et al. Chronic comorbidities
302 in children and adolescents with perinatally acquired HIV infection in sub-Saharan Africa in the era of
303 antiretroviral therapy. *The Lancet Child & Adolescent Health*. 2020;4(9):688-98.
- 304 14. Gulati S, Langman C. Chronic kidney disease in children. 2020.
- 305 15. Swanepoel CR, Atta MG, D'Agati VD, Estrella MM, Fogo AB, Naicker S, et al. Kidney
306 disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global
307 Outcomes (KDIGO) Controversies Conference. *Kidney international*. 2018;93(3):545-59.
- 308 16. Becherucci F, Roperto RM, Materassi M, Romagnani P. Chronic kidney disease in children.
309 *Clinical kidney journal*. 2016;9(4):583-91.

- 310 17. Schwartz GJ, Schneider MF, Maier PS, Moxey-Mims M, Dharnidharka VR, Warady BA, et
311 al. Improved equations estimating GFR in children with chronic kidney disease using an
312 immunonephelometric determination of cystatin C. *Kidney International*. 2012;82(4):445-53.
- 313 18. Selistre L, Rabilloud M, Cochat P, de Souza V, Iwaz J, Lemoine S, et al. Comparison of the
314 Schwartz and CKD-EPI equations for estimating glomerular filtration rate in children, adolescents,
315 and adults: a retrospective cross-sectional study. *PLoS medicine*. 2016;13(3):e1001979.
- 316 19. Filler G, Ferris M, Gattineni J. Assessment of kidney function in children, adolescents, and
317 young adults. *Pediatric Nephrology: Springer*; 2022. p. 145-71.
- 318 20. Delanaye P, Glassock RJ, Pottel H, Rule AD. An age-calibrated definition of chronic kidney
319 disease: rationale and benefits. *The Clinical Biochemist Reviews*. 2016;37(1):17.
- 320 21. Lameire NH, Levin A, Kellum JA, Cheung M, Jadoul M, Winkelmayr WC, et al.
321 Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney
322 Disease: Improving Global Outcomes (KDIGO) Consensus Conference. *Kidney international*.
323 2021;100(3):516-26.
- 324 22. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, et al. Kidney
325 Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice
326 guideline for the evaluation and management of chronic kidney disease. *Kidney international*
327 supplements. 2013;3(1):1-150.
- 328 23. Inc. RD. CYSC2: Tina-quant Cystatin C Gen.2. 2023.
- 329 24. Phillips NJ, Thomas KGF, Myer L, Sacktor N, Zar HJ, Stein DJ, et al. Screening for HIV-
330 associated neurocognitive disorders in perinatally infected adolescents: youth-International HIV
331 Dementia Scale validation. *AIDS*. 2019;33(5).
- 332 25. Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and
333 Management of Youth-Onset Type 2 Diabetes: A Position Statement by the American Diabetes
334 Association. *Diabetes Care*. 2018;41(12):2648-68.
- 335 26. Organization WH. Haemoglobin concentrations for the diagnosis of anaemia and assessment
336 of severity. World Health Organization; 2011.
- 337 27. NHS North Bristol. Children's Reference Ranges for FBC Bristol [Available from:
338 <https://www.nbt.nhs.uk/sites/default/files/Childrens%20FBC%20Reference%20Ranges.pdf>.
- 339 28. Mayo Clinic Laboratories. Complete Blood Cell Count (CBC) with Differential, Blood: Mayo
340 Foundation for Medical Education and Research.; 2024 [cited 2024 30th January]. Available from:
341 <https://pediatric.testcatalog.org/show/KS>.
- 342 29. Gligoroska JP, Gontarev S, Dejanova B, Todorovska L, Stojmanova DS, Manchevska S. Red
343 blood cell variables in children and adolescents regarding the age and sex. *Iranian journal of public*
344 *health*. 2019;48(4):704.
- 345 30. Mayo Clinic Laboratories. Parathyroid Hormone, Serum: Mayo Foundation for Medical
346 Education and Research.; 2024 [cited 2024 30th January]. Available from:
347 <https://pediatric.testcatalog.org/show/BUN>.
- 348 31. Lietman SA, Germain-Lee EL, Levine MA. Hypercalcemia in children and adolescents. *Curr*
349 *Opin Pediatr*. 2010;22(4):508-15.

- 350 32. KDOQI N. Clinical practice guidelines for bone metabolism and disease in children with
351 chronic kidney disease. *Am J Kidney Dis.* 2005;46:S1-S100.
- 352 33. Bazydlo LAL, Needham M, Harris NS. Calcium, Magnesium, and Phosphate. *Laboratory*
353 *Medicine.* 2014;45(1):e44-e50.
- 354 34. Mayo Clinic Laboratories. Basic Metabolic Panel, Serum: Mayo Foundation for Medical
355 Education and Research.; 2024 [Available from: <https://pediatric.testcatalog.org/show/BMAMA>].
- 356 35. UNFPA. UNFPA SUPPORT TO THE HIV RESPONSE – AN OVERVIEW (2016 to 2019).
357 Geneva: United Nations 2020.
- 358 36. Bhimma R. HIV-Related Kidney Diseases. In: Bobat R, editor. *HIV Infection in Children and*
359 *Adolescents.* Cham: Springer International Publishing; 2020. p. 143-52.
- 360 37. George C, Mogueo A, Okpechi I, Echouffo-Tcheugui JB, Kengne AP. Chronic kidney disease
361 in low-income to middle-income countries: the case for increased screening. *BMJ Glob Health.*
362 2017;2(2):e000256.
- 363 38. Clement EZ, Collins OO, Lisa AM. Laboratory Reference Intervals in Africa. In: Terry EM,
364 editor. *Blood Cell.* Rijeka: IntechOpen; 2012. p. Ch. 15.
- 365 39. Buchanan AM, Fiorillo SP, Omondi MW, Cunningham CK, Crump JA. Establishment of
366 biochemistry reference values for healthy Tanzanian infants, children and adolescents in Kilimanjaro
367 Region. *Tropical medicine & international health : TM & IH.* 2015;20(11):1569-77.
- 368 40. Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, et al. Disordered
369 FGF23 and mineral metabolism in children with CKD. *Clinical Journal of the American Society of*
370 *Nephrology.* 2014;9(2):344-53.
- 371 41. Wesseling K, Bakkaloglu S, Salusky I. Chronic kidney disease mineral and bone disorder in
372 children. *Pediatric Nephrology.* 2008;23(2):195-207.
- 373 42. Khatri M, Zitovsky J, Lee D, Nayyar K, Fazzari M, Grant C. The association between serum
374 chloride levels and chronic kidney disease progression: a cohort study. *BMC nephrology.*
375 2020;21(1):1-10.
- 376 43. Adiele DK, Ojinnaka NC, Okafor HU, Chinawa JM. Blood pressure trend in children with
377 chronic kidney disease in Nigeria, Sub-Saharan African region. *Nigerian Journal of Medicine.*
378 2023;32(4):407-11.
- 379 44. Schrauben SJ, Berns JS. Chapter 30 - Hematologic Complications of Chronic Kidney
380 Disease—Anemia and Platelet Disorders. In: Kimmel PL, Rosenberg ME, editors. *Chronic Renal*
381 *Disease (Second Edition):* Academic Press; 2020. p. 463-75.
- 382 45. Rayner HC, Thomas ME, Milford DV. Full Blood Count: Haematological Changes in Kidney
383 Diseases. *Understanding Kidney Diseases.* Cham: Springer International Publishing; 2020. p. 207-17.
- 384